Kanerva J - Search Results

1

Loss at 12p detected by comparative genomic hybridization (CGH): association with TEL-AML1 fusion and favorable prognostic features in childhood acute lymphoblastic leukemia (ALL). A multi-institutional study.

Kanerva J, Niini T, Vettenranta K, Riikonen P, Mäkipernaa A, Karhu R, Knuutila S, Saarinen-Pihkala UM. Kanerva J, et al. Med Pediatr Oncol. 2001 Nov;37(5):419-25. doi: 10.1002/mpo.1224. Med Pediatr Oncol. 2001. PMID: 11745869

2

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.

Rechl V, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, Eich H, Ek T, Gelderblom H, Hardes J, Haveman LM, Hartmann W, Hauser P, Heesen P, Jürgens H, Kanerva J, Kühne T, Raciborska A, Rascon J, Streitbürger A, Uhlenbruch Y, Timmermann B, Kersting J, Pham MT, Dirksen U. Rechl V, et al. Among authors: kanerva j. Sarcoma. 2024 Mar 16;2024:4751914. doi: 10.1155/2024/4751914. eCollection 2024. Sarcoma. 2024. PMID: 38524902 Free PMC article.

3

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement.

Green D, van Ewijk R, Tirtei E, Andreou D, Baecklund F, Baumhoer D, Bielack SS, Botchu R, Boye K, Brennan B, Capra M, Cottone L, Dirksen U, Fagioli F, Fernandez N, Flanagan AM, Gambarotti M, Gaspar N, Gelderblom H, Gerrand C, Gomez-Mascard A, Hardes J, Hecker-Nolting S, Kabickova E, Kager L, Kanerva J, Kester LA, Kuijjer ML, Laurence V, Lervat C, Marchais A, Marec-Berard P, Mendes C, Merks JHM, Ory B, Palmerini E, Pantziarka P, Papakonstantinou E, Piperno-Neumann S, Raciborska A, Roundhill EA, Rutkauskaite V, Safwat A, Scotlandi K, Staals EL, Strauss SJ, Surdez D, Sys GML, Tabone MD, Toulmonde M, Valverde C, van de Sande MAJ, Wörtler K, Campbell-Hewson Q, McCabe MG, Nathrath M. Green D, et al. Among authors: kanerva j. Clin Cancer Res. 2024 Aug 15;30(16):3395-3406. doi: 10.1158/1078-0432.CCR-24-0101. Clin Cancer Res. 2024. PMID: 38869831 Free PMC article. Review.

4

Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL.

Kanerva J, Tiirikainen M, Mäkipernaa A, Riikonen P, Möttönen M, Salmi TT, Krusius T, Saarinen-Pihkala UM. Kanerva J, et al. Pediatr Hematol Oncol. 1998 Jan-Feb;15(1):11-21. doi: 10.3109/08880019809009504. Pediatr Hematol Oncol. 1998. PMID: 9509502

5

Reemphasis on lymphoblast L2 morphology as a poor prognostic factor in childhood acute lymphoblastic leukemia.

Kanerva J, Saarinen-Pihkala UM, Riikonen P, Mäkipernaa A, Möttönen M, Salmi TT. Kanerva J, et al. Med Pediatr Oncol. 1999 Oct;33(4):388-94. doi: 10.1002/(sici)1096-911x(199910)33:4<388::aid-mpo8>3.0.co;2-n. Med Pediatr Oncol. 1999. PMID: 10491548

6

Comparative genomic hybridization and conventional cytogenetic analyses in childhood acute myeloid leukemia.

Huhta T, Vettenranta K, Heinonen K, Kanerva J, Larramendy ML, Mahlamäki E, Saarinen-Pihkala UM, Knuutila S. Huhta T, et al. Among authors: kanerva j. Leuk Lymphoma. 1999 Oct;35(3-4):311-5. doi: 10.3109/10428199909145735. Leuk Lymphoma. 1999. PMID: 10706455

7

AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia.

Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. Niini T, et al. Among authors: kanerva j. Haematologica. 2000 Apr;85(4):362-6. Haematologica. 2000. PMID: 10756360

8

Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up.

Kanerva J, Tiirikainen MI, Mäkipernaa A, Riikonen P, Möttönen M, Salmi TT, Krusius T, Saarinen-Pihkala UM. Kanerva J, et al. Pediatr Hematol Oncol. 2001 Jan-Feb;18(1):27-36. doi: 10.1080/088800101750059837. Pediatr Hematol Oncol. 2001. PMID: 11205837

9

Minimal residual disease by metaphase FISH in children with ALL: clonal cells during or after chemotherapy may not predict relapse.

Kanerva J, Vettenranta K, Autio K, Knuutila S, Saarinen-Pihkala UM. Kanerva J, et al. Leuk Res. 2002 Jun;26(6):545-50. doi: 10.1016/s0145-2126(01)00167-9. Leuk Res. 2002. PMID: 12007502

10

Favorable outcome in 20-year follow-up of children with very-low-risk ALL and minimal standard therapy, with special reference to TEL-AML1 fusion.

Kanerva J, Saarinen-Pihkala UM, Niini T, Riikonen P, Möttönen M, Mäkipernaa A, Salmi TT, Vettenranta K, Knuutila S. Kanerva J, et al. Pediatr Blood Cancer. 2004 Jan;42(1):30-5. doi: 10.1002/pbc.10417. Pediatr Blood Cancer. 2004. PMID: 14752791

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters